Website Logo

Press

Keep up-to-date with relevant news, important announcements and key market insights.

READ MORE
FEATURED

G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program in the United States

Download here

About Bionical Emas

Bionical Emas is the only Contract Research Organization that combines Clinical Development, Clinical Trial Supply (CTS) and Early Access Programs (EAP) to deliver a unique, seamless approach to bring life-changing medicines to patients around the world.

READ MORE

G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program in the United States

READ MORE

Let’s Face This Together: Bionical Emas supports rare disease charity, Same But Different

READ MORE

Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States

READ MORE

Women In Healthcare – PharmaTimes May 2020

READ MORE

The Early Access Voyage – Rare Revolution Spring 2020

READ MORE

A Statement From The Bionical Emas Group On Guidance & Measures Regarding COVID-19

READ MORE

PharmaMar and Bionical Emas launch Expanded Access Program for lurbinectedin in relapsed Small Cell Lung Cancer in the U.S.